Medical Condition News

RSS

Researchers create audio CDs to encourage physical activity among school students

The National Institutes of Health has awarded Albert Einstein College of Medicine of Yeshiva University $1.22 million to combat childhood obesity in the Bronx.

24 Mar 2010

Medical imaging benefits outweigh radiation risks, says ESC

Cardiac nuclear imaging and computed tomography angiography (CCTA) still have an important role to play in cardiac disease diagnosis, say experts from the European Society of Cardiology (ESC).

24 Mar 2010

Renowned leaders to discuss latest findings in early-stage drug development for cancer

When people think of cancer treatment, chemotherapy infusions, injections and pills often come to mind. These treatments result from extensive research and testing in drug development. But how does the process begin?

24 Mar 2010

Children with neurofibromatosis more likely to have cardiovascular problems

Researchers have discovered how a genetic disease known mainly for its life-threatening tumors also can cause sudden death from cardiovascular disease in children, and are mounting a clinical trial to develop treatments for the problem.

24 Mar 2010

New breakthrough technology makes it easier to investigate brain physiology

Thanks to new technology developed by researchers in Lund, it has for the first time become possible to measure blood flow in the brain directly and continuously.

24 Mar 2010

HPV test could help predict risk of cervical cancer, but more research needed

Testing for the human papillomavirus (HPV) - the major cause of cervical cancer - may not help to identify women who are at risk of the disease, a new UK study suggests.

24 Mar 2010

Age and gender play a major role in how people respond to stress

Age and gender play a major role in how people respond to stress, according to a new study on 20-to-64-year-olds. Published in the journal Psychophysiology, the investigation was led by scientists from the Universit- de Montr-al and the Montreal Heart Institute in collaboration with colleagues from the Universit- du Qu-bec - Montr-al and McGill University.

23 Mar 2010

St. Jude Medical's Brio DBS system for treating Parkinson’s disease receives Australian TGA approval

St. Jude Medical, Inc., a global medical device company, today announced regulatory and reimbursement approval from the Australian Therapeutic Goods Administration of its Brio™ deep brain stimulation system for treating the symptoms of Parkinson’s disease.

23 Mar 2010

Portola Pharmaceuticals commences Phase 1 trial of PRT062607 for chronic inflammatory diseases

Portola Pharmaceuticals, Inc. today announced that it has initiated its first in human Phase 1 trial in healthy volunteers of PRT062607, a novel, oral Syk-specific kinase inhibitor in development to treat chronic inflammatory diseases, including rheumatoid arthritis (RA), and certain cancers, including non-Hodgkin's lymphoma and chronic lymphocytic leukemia. In preclinical in vivo models of RA, PRT062607 was shown to reduce inflammation in a dose-dependent manner.

23 Mar 2010

Merck Serono, EMD Serono suspend global clinical development program for Stimuvax temporarily

Oncothyreon Inc. today announced that Merck Serono, a division of Merck KGaA of Darmstadt, Germany, and its U.S. affiliate, EMD Serono, Inc., have temporarily suspended the worldwide clinical development program for Stimuvax(R) (BLP25 liposomal vaccine). The suspension is the result of a suspected unexpected serious adverse reaction in a patient with multiple myeloma participating in an exploratory clinical trial.

23 Mar 2010

Celladon Corporation receives USPTO notice of allowance covering MYDICAR for advanced heart failure

Celladon Corp. announced today that the United States Patent and Trademark Office (USPTO) has granted a notice of allowance for a broad patent covering the company's lead drug candidate MYDICAR®, a genetically targeted enzyme replacement therapy for advanced heart failure. The patent will be issued to The Regents of the University of California and licensed exclusively to Celladon.

23 Mar 2010

ReGear Life Sciences achieves preferred partner status with Genesis Rehab Services

ReGear Life Sciences, Inc. announces that it has been named a Preferred Partner to Genesis Rehab Services.

23 Mar 2010

EMA validates InterMune's pirfenidone MAA for IPF

InterMune, Inc. today announced that the company's Marketing Authorization Application (MAA), submitted on March 2 seeking approval of pirfenidone for the treatment of idiopathic pulmonary fibrosis (IPF) in adults, was validated by the European Medicines Agency (EMA). Validation of the MAA by the EMA indicates that the application is complete and that the review process will begin on March 24. The proposed trade name for pirfenidone in both the United States and Europe is Esbriet®.

23 Mar 2010

BioSante Pharmaceuticals receives FDA Orphan Drug designation for GVAX AML Vaccine

BioSante Pharmaceuticals, Inc. today announced positive GVAX AML Vaccine results and BioSante’s receipt of Orphan Drug designation from the FDA’s Office of Orphan Products Development for GVAX AML Vaccine in the treatment of acute myeloid leukemia. This Orphan Drug designation is the second GVAX cancer vaccine from BioSante to secure FDA orphan drug designation.

23 Mar 2010

Aradigm reports net loss of $3.4M for fourth-quarter 2009

Aradigm Corporation today announced financial results for the fourth quarter and full year ended December 31, 2009.

23 Mar 2010

Auditory brainstem implants for adults with damaged cochlear nerves

If a siren sounded but you were deaf, might you still be able to hear the sound?

23 Mar 2010

5% increase in tobacco taxation needed to account for high cost of smoking to society

A leading think tank has recommended a five per cent rise in tobacco taxation in the next Budget to reflect the high cost of smoking to society.

23 Mar 2010

Itamar Medical's EndoPAT systems in use around the world to diagnose cardiovascular disease

At the 2010 ACC conference held in Atlanta, GA, six new studies based on the PAT™ (Peripheral Arterial Tone) signal focused on assessing cardiovascular risk by measuring and improving endothelial health. Of those, two studies from Japan focused on assessing cardiovascular risk in both high and low risk patient populations.

23 Mar 2010

People with Alzheimer's disease experience higher rate of cognitive decline: New study

People with Alzheimer's disease experience a rate of cognitive decline four times greater than those with no cognitive impairment according to a new study by researchers at Rush University Medical Center in Chicago.

23 Mar 2010

Clinical Data completes NDA submission for vilazodone

Clinical Data, Inc., today announced that the Company has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for vilazodone for the treatment of major depressive disorder (MDD). Vilazodone is a dual-acting potent and selective serotonin reuptake inhibitor and a 5-HT1A receptor partial agonist. The Company expects that the NDA submission, if accepted, will be subject to a standard review.

23 Mar 2010

Medical Condition News

Researchers create audio CDs to encourage physical activity among school students

Medical imaging benefits outweigh radiation risks, says ESC

Renowned leaders to discuss latest findings in early-stage drug development for cancer

Children with neurofibromatosis more likely to have cardiovascular problems

New breakthrough technology makes it easier to investigate brain physiology

HPV test could help predict risk of cervical cancer, but more research needed

Age and gender play a major role in how people respond to stress

St. Jude Medical's Brio DBS system for treating Parkinson’s disease receives Australian TGA approval

Portola Pharmaceuticals commences Phase 1 trial of PRT062607 for chronic inflammatory diseases

Merck Serono, EMD Serono suspend global clinical development program for Stimuvax temporarily

Celladon Corporation receives USPTO notice of allowance covering MYDICAR for advanced heart failure

ReGear Life Sciences achieves preferred partner status with Genesis Rehab Services

EMA validates InterMune's pirfenidone MAA for IPF

BioSante Pharmaceuticals receives FDA Orphan Drug designation for GVAX AML Vaccine

Aradigm reports net loss of $3.4M for fourth-quarter 2009

Auditory brainstem implants for adults with damaged cochlear nerves

5% increase in tobacco taxation needed to account for high cost of smoking to society

Itamar Medical's EndoPAT systems in use around the world to diagnose cardiovascular disease

People with Alzheimer's disease experience higher rate of cognitive decline: New study

Clinical Data completes NDA submission for vilazodone

How can microdialysis benefit drug development

Global and Local Efforts to Take Action Against Hepatitis

Addressing Important Cardiac Biology Questions with Shotgun Top-Down Proteomics

Latest News